Evommune Statistics
Total Valuation
Evommune has a market cap or net worth of $291.10 million. The enterprise value is $130.66 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evommune has 41.35 million shares outstanding. The number of shares has increased by 1,950.51% in one year.
| Current Share Class | 41.35M |
| Shares Outstanding | 41.35M |
| Shares Change (YoY) | +1,950.51% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 51.83% |
| Float | 24.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 465.76 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.52, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.52 |
| Quick Ratio | 8.33 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.53% and return on invested capital (ROIC) is -45.59%.
| Return on Equity (ROE) | -69.53% |
| Return on Assets (ROA) | -41.99% |
| Return on Invested Capital (ROIC) | -45.59% |
| Return on Capital Employed (ROCE) | -47.28% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.36M |
| Employee Count | 48 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -63.50% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 16.87 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 1,041,197 |
Short Selling Information
The latest short interest is 3.39 million, so 8.19% of the outstanding shares have been sold short.
| Short Interest | 3.39M |
| Short Previous Month | 2.89M |
| Short % of Shares Out | 8.19% |
| Short % of Float | 13.87% |
| Short Ratio (days to cover) | 3.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -121.89M |
| Pretax Income | -113.07M |
| Net Income | -113.07M |
| EBITDA | -120.13M |
| EBIT | -121.89M |
| Earnings Per Share (EPS) | -$3.59 |
Full Income Statement Balance Sheet
The company has $168.64 million in cash and $8.19 million in debt, with a net cash position of $160.45 million or $3.88 per share.
| Cash & Cash Equivalents | 168.64M |
| Total Debt | 8.19M |
| Net Cash | 160.45M |
| Net Cash Per Share | $3.88 |
| Equity (Book Value) | 251.37M |
| Book Value Per Share | 6.91 |
| Working Capital | 154.08M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$90.40 million and capital expenditures -$603,000, giving a free cash flow of -$91.00 million.
| Operating Cash Flow | -90.40M |
| Capital Expenditures | -603,000 |
| Depreciation & Amortization | 1.77M |
| Net Borrowing | -456,000 |
| Free Cash Flow | -91.00M |
| FCF Per Share | -$2.20 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evommune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,950.51% |
| Shareholder Yield | -1,950.51% |
| Earnings Yield | -50.95% |
| FCF Yield | -31.26% |
Analyst Forecast
The average price target for Evommune is $21.89, which is 210.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.89 |
| Price Target Difference | 210.94% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -52.42% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evommune has an Altman Z-Score of 12.23 and a Piotroski F-Score of 2.
| Altman Z-Score | 12.23 |
| Piotroski F-Score | 2 |